| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5be9456a74cc707cc9ad4370982a402
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96c84c8efcc6aeaf350488384f4952ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c574a3c3bb2c63c9e2fc4ae65d060a8b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2063
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4891
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-741 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-741
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-135 |
| filingDate |
2019-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95162249fe28c528836b7d2e3c3bae54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4297273676ced9e6dfad7fc07e703dd2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f62b53e0f3b954e47e68acea1a5aa533
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02da88a8bff73e61984eeb7fd3766ff5 |
| publicationDate |
2021-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3886882-A1 |
| titleOfInvention |
Hafnia alvei formulations |
| abstract |
The present invention relates to composition essentially consisting of Hafnia alvei probiotic strain expressing the ClpB protein; wherein the ClpB protein is in an amount of at least 0.7 % (w/w) in weight relative to the total weight of the composition; and the ratio of the total number of Hafnia alvei Colony Forming Units to the total Hafnia alvei cell number ranges from 10-4 to 0.8. The invention further relates to oral dosage forms, namely gastro-resistant capsules comprising the composition of the invention. |
| priorityDate |
2018-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |